Your browser doesn't support javascript.
loading
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer, Eric P; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Muñoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Zhou, Xuan; Karantza, Vassiliki; Mejia, Jaime; Cortes, Javier.
Afiliación
  • Winer EP; Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: eric_winer@dfci.harvard.edu.
  • Lipatov O; Medical Oncology, Republican Clinical Oncology Dispensary, Ufa, Republic of Bashkortostan, Russia.
  • Im SA; Internal Medicine, Seoul National University, Seoul, South Korea.
  • Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Centre National de la Recherche Scientifique, French National Institute of Health and Medical Research, Marseille, France.
  • Muñoz-Couselo E; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Lee KS; Center for Breast Cancer, National Cancer Center, Goyang, South Korea.
  • Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK.
  • Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Testa L; Breast Medical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade do Estado do São Paulo, São Paulo, Brazil.
  • Witzel I; Department of Gynaecology, University Medical Center Hamburg, Hamburg, Germany.
  • Ohtani S; Surgical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Turner N; Breast Unit, Royal Marsden National Health Service Foundation Trust, London, UK.
  • Zambelli S; Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.
  • Harbeck N; Breast Center, Ludwig-Maximilians-University, University Hospital, Munich, Germany.
  • Andre F; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Villejuif, France.
  • Dent R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Zhou X; Division of Medical Oncology, Merck, Kenilworth, NJ, USA.
  • Karantza V; Division of Medical Oncology, Merck, Kenilworth, NJ, USA.
  • Mejia J; Division of Medical Oncology, Merck, Kenilworth, NJ, USA.
  • Cortes J; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Lancet Oncol ; 22(4): 499-511, 2021 04.
Article en En | MEDLINE | ID: mdl-33676601
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Antígeno B7-H1 / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article